Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study

Daniela Pugliese, Marco Daperno, Gionata Fiorino, Edoardo Savarino, Elena Mosso, Livia Biancone, Anna Testa, Lucio Sarpi, Maria Cappello, Giorgia Bodini, Flavio Caprioli, Stefano Festa, Gabriella Laino, Giovanni Maconi, Silvia Mazzuoli, Giammarco Mocci, Alessandro Sartini, Alessandra D'Amore, Stefano Alivernini, Elisa GremeseAlessandro Armuzzi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis. Aims: to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription. Methods: This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD. Results: Seventy patients (64 Crohn's disease / 6 ulcerative colitis) were enrolled. The median follow-up on ustekinumab therapy was 10.7 months (range, 1.4–67.3). Twelve patients (17.1%) withdrew the treatment after a median of 7.4 months (range, 0.9–23.8). The cumulative probability of maintaining ustekinumab treatment was 97.1% at 6 months and 77.1% at 12 months. Among the 56 patients with baseline active IBD, 34 (60.7%) were in clinical remission at the last follow-up visit. Their cumulative probability of achieving clinical remission was 84.7% and 63.9% at 6 and 12 months, respectively. Two patients stopped ustekinumab for an adverse event. Conclusions: Subcutaneous ustekinumab had a good effectiveness profile for IBD patients treated for concomitant dermatological or rheumatological conditions.

Original languageEnglish
Pages (from-to)972-977
JournalDigestive and Liver Disease
Volume51
Issue number7
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Psoriatic Arthritis
Inflammatory Bowel Diseases
Psoriasis
Ustekinumab
Therapeutics
Ulcerative Colitis
Crohn Disease
Multicenter Studies
Prescriptions
Retrospective Studies
Maintenance

Keywords

  • Crohn's disease
  • Psoriasis
  • Psoriatic arthritis
  • Ulcerative colitis
  • Ustekinumab

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis : An IG-IBD study. / Pugliese, Daniela; Daperno, Marco; Fiorino, Gionata; Savarino, Edoardo; Mosso, Elena; Biancone, Livia; Testa, Anna; Sarpi, Lucio; Cappello, Maria; Bodini, Giorgia; Caprioli, Flavio; Festa, Stefano; Laino, Gabriella; Maconi, Giovanni; Mazzuoli, Silvia; Mocci, Giammarco; Sartini, Alessandro; D'Amore, Alessandra; Alivernini, Stefano; Gremese, Elisa; Armuzzi, Alessandro.

In: Digestive and Liver Disease, Vol. 51, No. 7, 01.01.2019, p. 972-977.

Research output: Contribution to journalArticle

Pugliese, D, Daperno, M, Fiorino, G, Savarino, E, Mosso, E, Biancone, L, Testa, A, Sarpi, L, Cappello, M, Bodini, G, Caprioli, F, Festa, S, Laino, G, Maconi, G, Mazzuoli, S, Mocci, G, Sartini, A, D'Amore, A, Alivernini, S, Gremese, E & Armuzzi, A 2019, 'Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study', Digestive and Liver Disease, vol. 51, no. 7, pp. 972-977. https://doi.org/10.1016/j.dld.2019.03.007
Pugliese, Daniela ; Daperno, Marco ; Fiorino, Gionata ; Savarino, Edoardo ; Mosso, Elena ; Biancone, Livia ; Testa, Anna ; Sarpi, Lucio ; Cappello, Maria ; Bodini, Giorgia ; Caprioli, Flavio ; Festa, Stefano ; Laino, Gabriella ; Maconi, Giovanni ; Mazzuoli, Silvia ; Mocci, Giammarco ; Sartini, Alessandro ; D'Amore, Alessandra ; Alivernini, Stefano ; Gremese, Elisa ; Armuzzi, Alessandro. / Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis : An IG-IBD study. In: Digestive and Liver Disease. 2019 ; Vol. 51, No. 7. pp. 972-977.
@article{087b81c268e3453c8d5999e0575ef6e7,
title = "Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study",
abstract = "Background: Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis. Aims: to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription. Methods: This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD. Results: Seventy patients (64 Crohn's disease / 6 ulcerative colitis) were enrolled. The median follow-up on ustekinumab therapy was 10.7 months (range, 1.4–67.3). Twelve patients (17.1{\%}) withdrew the treatment after a median of 7.4 months (range, 0.9–23.8). The cumulative probability of maintaining ustekinumab treatment was 97.1{\%} at 6 months and 77.1{\%} at 12 months. Among the 56 patients with baseline active IBD, 34 (60.7{\%}) were in clinical remission at the last follow-up visit. Their cumulative probability of achieving clinical remission was 84.7{\%} and 63.9{\%} at 6 and 12 months, respectively. Two patients stopped ustekinumab for an adverse event. Conclusions: Subcutaneous ustekinumab had a good effectiveness profile for IBD patients treated for concomitant dermatological or rheumatological conditions.",
keywords = "Crohn's disease, Psoriasis, Psoriatic arthritis, Ulcerative colitis, Ustekinumab",
author = "Daniela Pugliese and Marco Daperno and Gionata Fiorino and Edoardo Savarino and Elena Mosso and Livia Biancone and Anna Testa and Lucio Sarpi and Maria Cappello and Giorgia Bodini and Flavio Caprioli and Stefano Festa and Gabriella Laino and Giovanni Maconi and Silvia Mazzuoli and Giammarco Mocci and Alessandro Sartini and Alessandra D'Amore and Stefano Alivernini and Elisa Gremese and Alessandro Armuzzi",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.dld.2019.03.007",
language = "English",
volume = "51",
pages = "972--977",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "7",

}

TY - JOUR

T1 - Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis

T2 - An IG-IBD study

AU - Pugliese, Daniela

AU - Daperno, Marco

AU - Fiorino, Gionata

AU - Savarino, Edoardo

AU - Mosso, Elena

AU - Biancone, Livia

AU - Testa, Anna

AU - Sarpi, Lucio

AU - Cappello, Maria

AU - Bodini, Giorgia

AU - Caprioli, Flavio

AU - Festa, Stefano

AU - Laino, Gabriella

AU - Maconi, Giovanni

AU - Mazzuoli, Silvia

AU - Mocci, Giammarco

AU - Sartini, Alessandro

AU - D'Amore, Alessandra

AU - Alivernini, Stefano

AU - Gremese, Elisa

AU - Armuzzi, Alessandro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis. Aims: to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription. Methods: This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD. Results: Seventy patients (64 Crohn's disease / 6 ulcerative colitis) were enrolled. The median follow-up on ustekinumab therapy was 10.7 months (range, 1.4–67.3). Twelve patients (17.1%) withdrew the treatment after a median of 7.4 months (range, 0.9–23.8). The cumulative probability of maintaining ustekinumab treatment was 97.1% at 6 months and 77.1% at 12 months. Among the 56 patients with baseline active IBD, 34 (60.7%) were in clinical remission at the last follow-up visit. Their cumulative probability of achieving clinical remission was 84.7% and 63.9% at 6 and 12 months, respectively. Two patients stopped ustekinumab for an adverse event. Conclusions: Subcutaneous ustekinumab had a good effectiveness profile for IBD patients treated for concomitant dermatological or rheumatological conditions.

AB - Background: Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis. Aims: to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription. Methods: This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD. Results: Seventy patients (64 Crohn's disease / 6 ulcerative colitis) were enrolled. The median follow-up on ustekinumab therapy was 10.7 months (range, 1.4–67.3). Twelve patients (17.1%) withdrew the treatment after a median of 7.4 months (range, 0.9–23.8). The cumulative probability of maintaining ustekinumab treatment was 97.1% at 6 months and 77.1% at 12 months. Among the 56 patients with baseline active IBD, 34 (60.7%) were in clinical remission at the last follow-up visit. Their cumulative probability of achieving clinical remission was 84.7% and 63.9% at 6 and 12 months, respectively. Two patients stopped ustekinumab for an adverse event. Conclusions: Subcutaneous ustekinumab had a good effectiveness profile for IBD patients treated for concomitant dermatological or rheumatological conditions.

KW - Crohn's disease

KW - Psoriasis

KW - Psoriatic arthritis

KW - Ulcerative colitis

KW - Ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=85064210954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064210954&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2019.03.007

DO - 10.1016/j.dld.2019.03.007

M3 - Article

AN - SCOPUS:85064210954

VL - 51

SP - 972

EP - 977

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 7

ER -